Prognosis and Economics

We are currently recruiting subjects from 33 centres in Sweden, see Table below. We have closed Högsbo and Visby due to a lack of principal investigators. The average recruitment has been 30 pat/months during the last 10 months.

Included in the EFFECTS study as of 31/10/2017

We now aim to include 35 patients per months.

Figure 1 illustrates the inclusion in EFFECTS per month. The blue line represents the included patients (Results). The brown line is a prognosis with 30 pat/month and the green line denotes 35 pat/month.

Work plan with milestones

Figure 2 below illustrates some of the important milestones for EFFECTS. This is how we want to achieve our goals.

  • Application for extension of grant from the Swedish Research Council: Jan 2018
  • Ordering last batch of medication: May 2018
  • Last patient in March 2019 (ideally) or July 2019 (probably)
  • Compiling the database: From 2018 to 2020
  • Publications: Our preliminary plan is to present the main results at the European Stroke Organization Congress (ESOC) World Stroke Conference (WSC). In 2020 these two congresses will be merged into one in Vienna, Austria.
  • Pooling data for our two sister trials: 2020-2022
  • Planning and writing subgroup analysis: 2019-2023
Figure 2. Milestones for EFFECTS. The green arrow Last-patient in 35 denotes the inclusion rate of 35 pat/months with Last follow-up 35 one year later. Update of EFFECTS denotes a planned article for the whole cohort, not breaking the code


EFFECTS has received substantial economic support, totalling 36 006 500 SEK. The Swedish Research Council (Vetenskapsrådet, VR) has granted us 31 114 000 SEK, the largest ever grant from VR for a clinical study in Sweden. We currently have tenancies of VR funds up to the end of 2020, meaning that EFFECTS has stable finances.